Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Narratives
Your Valuation
🌎 Global
Global
United States
Australia
United Kingdom
Canada
India
China
Argentina
Austria
Bahrain
Bangladesh
Belgium
Bermuda
Botswana
Brazil
Bulgaria
Chile
Colombia
Croatia
Cyprus
Czech Republic
Denmark
Egypt
Estonia
Finland
France
Germany
Ghana
Greece
Hong Kong
Hungary
Iceland
Indonesia
Ireland
Israel
Italy
Ivory Coast
Jamaica
Japan
Jordan
Kenya
Kuwait
Latvia
Lithuania
Luxembourg
Malawi
Malaysia
Malta
Mauritius
Mexico
Morocco
Namibia
Netherlands
New Zealand
Nigeria
Norway
Oman
Pakistan
Palestinian Authority
Peru
Philippines
Poland
Portugal
Qatar
Romania
Russia
Saudi Arabia
Serbia
Singapore
Slovakia
Slovenia
South Africa
South Korea
Spain
Sri Lanka
Sweden
Switzerland
Taiwan
Tanzania
Thailand
Trinidad & Tobago
Tunisia
Turkey
Uganda
Ukraine
United Arab Emirates
Venezuela
Vietnam
Zambia
Zimbabwe
Create a narrative
Global Community
Our community narratives are driven by numbers and valuation.
Create a narrative
Community Investing Ideas
Global Weekly Picks
Airbnb
TI
TickerTickle
Community Contributor
Airbnb (ABNB): Still one of the most interesting bets in travel
Key insights Airbnb is changing from a travel-only app to a full lifestyle platform (stays, rentals, experiences) International markets are growing faster than the US, which is slowing down Product experience is improving a lot, with AI making search and booking easier Regulations are becoming a big risk, especially in Europe where listings are getting removed The way people move around the world has changed. It’s not only about holidays anymore.
View narrative
US$163.75
FV
27.8% undervalued
intrinsic discount
12.00%
Revenue growth p.a.
Set Fair Value
4
users have liked this narrative
0
users have commented on this narrative
11
users have followed this narrative
New
narrative
ING Groep
PI
PittTheYounger
Community Contributor
ING leads the pack when it comes to pivoting towards non-lending income
ING, of course, is a bank; and banks don't like falling interest rates, right? For the dominant stream of income is their core business model, i.e. borrowing short-term and lending long-term, reaping the difference in interest rates in the process.
View narrative
€27.92
FV
25.2% undervalued
intrinsic discount
9.00%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
3
users have followed this narrative
New
narrative
Coles Group
RO
Robbo
Community Contributor
Coles (ASX: COL): Safe, Steady, and Surprisingly Cheap
The supermarket chain Coles is the kind of “boring” business that may have been overlooked as an investment opportunity. Although it was divested from Wesfarmers in 2018, Coles’ heritage traces back to 1914 — giving it over 110 years of history.
View narrative
AU$22.00
FV
5.0% undervalued
intrinsic discount
8.72%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
1
users have followed this narrative
New
narrative
All companies
Popular
Undervalued
Overvalued
Load previous narratives
1911 Gold
RO
RockeTeller
Community Contributor
If gold reaches $4,000 per oz
To estimate the potential stock price of 1911 Gold Corp if gold reaches $4,000 per oz, we can consider the following: Current Resource Base : The company has a significant resource base, including: True North Mine: 1 million oz at 6 gpt. Ogama-Rockland: 300,000 oz at 8 gpt.
View narrative
CA$0.65
FV
60.0% undervalued
intrinsic discount
0%
Revenue growth p.a.
Set Fair Value
1
users have liked this narrative
0
users have commented on this narrative
1
users have followed this narrative
about 2 months ago
author updated this narrative
Novo Nordisk
KA
kapirey
Community Contributor
Novo Nordisk will see a 24% surge in profit margin paving way for growth
Today, July 29 Novo revised its full year 2025 guidance downward: Sales growht in local currencies now expected 8% - 14%. (down from 13% -21%.) Operating profit growth: now expected 10% -16%, ( down from 16% x24%).
View narrative
DKK 388.00
FV
17.4% undervalued
intrinsic discount
4.00%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
2
users have followed this narrative
14 days ago
author updated this narrative
Uber Technologies
CO
codepoet
Community Contributor
Highlighting its evolution, financial trajectory, strategic vision, and the key risks on the road ahead.
1. Platform Model: Mobility, Delivery & Logistics Uber operates a global two-sided marketplace , connecting riders, couriers, and freight shippers with independent drivers without owning vehicles or inventory.
View narrative
US$90.00
FV
0.6% overvalued
intrinsic discount
5.83%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
2
users have followed this narrative
Updated
narrative
Neurocrine Biosciences
KA
kapirey
Community Contributor
Neurocrine Biosciences is set to achieve a 40x future PE ratio with a 17% revenue boost
Pipeline Crenessity@ CRENESSITY Capsule 50/100 MG $766.66 packaging 50 MG 60u $45,999.60 packaging 100 MG 30u. Starts at approximately $21,338.71 USD for a monthly supply Ingrezza@ Ingrezza (valbenazine) As of July 2025 , the average pharmacy acquisition cost for Ingrezza capsules in the U.S. is approximately: $274.54 per capsule for the 60 mg and 80 mg strengths $250.16 per capsule for the 40 mg strength Other Products: Tetrabenazine Tablet 12.5 MG $62.52 Austedo Tablet 6 MG $100.06 Austedo XR Tablet 6 MG $100.06 Xenazine Tablet 12.5 MG $227.88 Assumptions Risks Risks and uncertainties associated with Neurocrine Biosciences' business and finances in general, risks and uncertainties associated with the commercialization of INGREZZA and CRENESSITY.
View narrative
US$244.80
FV
49.4% undervalued
intrinsic discount
17.00%
Revenue growth p.a.
Set Fair Value
1
users have liked this narrative
0
users have commented on this narrative
9
users have followed this narrative
17 days ago
author updated this narrative
Mycronic
MA
Mandelman
Community Contributor
Historically Cheap, but the Margin of Safety Is Still Thin
Catalysts Electronics-complexity super-cycle — AI datacentres, EVs and advanced display / semiconductor nodes require ever-finer photomasks, ultra-precise die bonding and higher-reliability SMT lines, directly fueling sales of Pattern Generators, dispensing/coating and photonics tools. Proven pricing power — gross margin has averaged 54 % over the past decade (≈ 40 % lowpint), showing customers pay a premium for Mycronic’s precision and uptime.
View narrative
SEK 232.58
FV
8.0% undervalued
intrinsic discount
12.00%
Revenue growth p.a.
Set Fair Value
1
users have liked this narrative
0
users have commented on this narrative
11
users have followed this narrative
about 2 months ago
author updated this narrative
DLocal
WY
WynnLevi
Community Contributor
DLocal's Future Growth Fueled by 35% Revenue and Profit Margin Boosts
1. Continuous Product and Service Expansion DLocal emphasizes continuous investment in developing new products and services.
View narrative
US$195.39
FV
94.5% undervalued
intrinsic discount
35.00%
Revenue growth p.a.
Set Fair Value
3
users have liked this narrative
0
users have commented on this narrative
25
users have followed this narrative
about 2 months ago
author updated this narrative
Americas Gold and Silver
AG
Agricola
Community Contributor
A case for TSXV:USA to reach USD $5.00 - $9.00 (CAD $7.30–$12.29) by 2029.
Americas Gold and Silver Corporation (TSXV: USA) – 5-Year Outlook (2025–2029) This analysis evaluates the potential performance of Americas Gold and Silver Corporation (TSXV: USA) over the next five years, based on the assumptions: successful production at Cosalá Operations (including the EC120 project) and the Galena Complex, a silver price of $100/oz, gold price of $4,000/oz, oil price of $60/barrel, 7.5% annual inflation, a gold and silver bull market from 2025–2029 and no stock dilution. All financial figures are in USD unless otherwise stated.
View narrative
CA$12.29
FV
88.0% undervalued
intrinsic discount
180.72%
Revenue growth p.a.
Set Fair Value
14
users have liked this narrative
5
users have commented on this narrative
60
users have followed this narrative
about 2 months ago
author updated this narrative
Medical Properties Trust
GF
GFB
Community Contributor
Bullish, buy more
Shorts are manipulating the stock. The fundamentals are too strong to ignore.
View narrative
US$13.09
FV
69.2% undervalued
intrinsic discount
2.82%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
1
users have followed this narrative
New
narrative
Rectifier Technologies
BU
Bucky
Community Contributor
This stock was affected by the Tritium Collapse (losing sales momentum for two years), but remains a significant and efficient supplier of E
This stock was affected by the Tritium Collapse (losing sales momentum for two years), but remains a significant and efficient supplier of EV Rectifiers. It has a large European customer as well as Australian Defence and Telecommunications.
View narrative
AU$0.08
FV
92.5% undervalued
intrinsic discount
86.38%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
1
users have followed this narrative
New
narrative
Value any company in seconds
Popular companies